Revolutionary New Treatment Regimens for Multidrug-Resistant Tuberculosis

The Lancet Infectious Diseases - United Kingdom
doi 10.1016/s1473-3099(19)30060-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Value of Pyrazinamide for Composition of New Treatment Regimens for Multidrug-Resistant Mycobacterium Tuberculosis in China

BMC Infectious Diseases
Infectious Diseases
2020English

Treatment Outcomes of Rifabutin-Containing Regimens for Rifabutin-Sensitive Multidrug-Resistant Pulmonary Tuberculosis

International Journal of Infectious Diseases
MedicineInfectious DiseasesMicrobiology
2017English

Bedaquiline: New Approach for Treatment of Multidrug-Resistant Tuberculosis

RUHS Journal of Health Science
2019English

Shorter Regimens for Multidrug-Resistant Tuberculosis Should Also Be Applicable in Europe

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2017English

Clofazimine for the Treatment of Multidrug-Resistant Tuberculosis

Clinical Microbiology and Infection
MedicineInfectious DiseasesMicrobiology
2019English

Hypokalemia Among Patients Receiving Treatment for Multidrug-Resistant Tuberculosis

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2004English

Multidrug Resistant Tuberculosis

British Medical Journal
Medicine
2015English

Final Treatment Outcomes of Multidrug- And Extensively Drug-Resistant Tuberculosis Patients in Latvia Receiving Delamanid-Containing Regimens

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2017English

Hepatotoxicity During Treatment for Multidrug-Resistant Tuberculosis: Occurrence, Management and Outcome

International Journal of Tuberculosis and Lung Disease
MedicinePulmonaryInfectious DiseasesRespiratory Medicine
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy